Your old cell phones could be worth a good amount of money, especially if they were part of a groundbreaking generation or are rare.

Canada Is Not for Sale' Hat Goes Viral After Trump Threats By Wa Lone and Kyaw Soe Oo (Reuters) - Donald Trump's verbal threats towards Canada are paying off for one entrepreneur, after the new U ...

Cellular signal ... means I cover wireless phones, plans, tablets, ereaders, and a whole lot more. I’ve always loved technology and have been forming opinions on consumer electronics since ...

As first spotted by Wired, there are currently about 9,000 eBay item listings for various smartphones that already have ...

Generally speaking, you'll find cell phone deals coming in two forms - first as an outright sale on an unlocked device, and secondly as part of a carrier-plan tie-in. The latter can be a bit ...

Instead, the phone relays the text messages using orbiting Starlink satellites, giving consumers a way to remain connected in cellular dead zones, similar to Apple’s Emergency SOS satellite ...

It looks like T-Mobile is now accepting customers into the free beta program for SpaceX’s cellular Starlink service—but only if you have the latest Samsung handsets. On Tuesday, a number of T ...

A new year is the perfect time to make sure you've got the best cell phone plan for your needs — and if you don't, it's time to consider your options for getting more data at a lower monthly cost.

Amazon Great Republic Day Sale 2025 sale is live with hundreds of deals We've handpicked the best tech deals you can grab on day 1 SBI credit card users can avail 10 percent additional discount ...

Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s ...

(RTTNews) - Johnson & Johnson (JNJ) and Intra-Cellular Therapies, Inc. (ITCI) announced Monday that they have entered into a definitive agreement under which Johnson & Johnson will acquire all ...

Johnson & Johnson on Monday said it has agreed to acquire Intra-Cellular Therapies, a developer of drugs for diseases of the brain, for $132 per share, or about $14.6 billion. The announcement of the ...